Taliglucerase alfa (Elelyso)

Elelyso (taliglucerase alfa) is covered only for FDA‑approved treatment of Type 1 Gaucher disease (not for other indications) in patients aged ≥4 years. Approval (up to 1 year) requires documentation of deficient β‑glucocerebrosidase activity or a GBA gene mutation, prescription by or consultation with an appropriate specialist (geneticist, endocrinologist, metabolic disorder/lysosomal storage disorder specialist), and dosing limited to 60 U/kg IV no more frequently than every 2 weeks.

"Elelyso is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.